Major companies committed to joining Medicare drug price negotiations; Boehringer Ingelheim introduced a low-cost version of its adalimumab biosimilar; schools begin to stock naloxone amid rising opioid deaths among young people.
Pharmaceutical companies including Johnson & Johnson, Merck, and Bristol Myers Squibb have agreed to participate in Medicare drug price negotiations with the federal government, according to the Biden administration, NBC News reported. The negotiations are expected to begin next year, with the negotiated prices taking effect in 2026. The drug companies are the makers of the first 10 prescription drugs subject to price negotiations, including medications for conditions like diabetes and rheumatoid arthritis. Lawsuits from some of the drug companies are still ongoing.
Boehringer Ingelheim has released an unbranded version of its biosimilar for AbbVie's Humira (adalimumab) in the United States with a list price at an 81% discount to the reference drug, according to Reuters. This move comes after the launch of a branded biosimilar, Cyltezo (adalimumab-adbm), priced at a 5% discount to Humira's list price. Boehringer Ingelheim's biosimilars for Humira are designated as interchangeable by the FDA, allowing them to be substituted for the original without prescriber consultation. With 8 adalimumab biosimilars entering the US market this year, competition among manufacturers is growing, and several are seeking interchangeability status with the FDA.
In Colorado, some school districts are facing a decision about whether to stock naloxone, a medication that rapidly reverses opioid overdoses, in their schools, according to KFF Health News. While more districts have enrolled in the state's program to obtain naloxone at a reduced cost or for free since passage of a state law in 2019, only about a third of Colorado districts had done so at the beginning of the current school year. The reluctance to stock naloxone is often due to concerns about stigma, providing a medical service, resupplying naloxone, and fears of the school being perceived as having a drug problem. However, health officials recommend its availability as opioid overdose deaths among young people continue to rise.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Initiating BP Medication Linked to Higher Fall, Fracture Risks in Nursing Home Residents
May 2nd 2024Among over 60,000 nursing home residents who initiated antihypertensive medication, rates of excess fractures due to falls per 100 person-years were as high as 5 among certain patient groups, such as those with dementia and high blood pressure (BP).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen